Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 142, Issue 3 PT B, Pages 951-959Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2021.06.040
Keywords
-
Categories
Ask authors/readers for more resources
Immune checkpoint blockade has revolutionized the treatment of various tumors, but it can lead to immune-related adverse events (irAEs) in the skin. This article reviews the reasons for using immune checkpoint blockade, current drugs, their applications in skin cancers, autoimmune manifestations in the skin, and the lack of preclinical modeling in this area.
Immune checkpoint blockade has revolutionized the treatment of multiple tumor types, including melanoma and nonmelanoma skin cancers. The use of immune checkpoint blockade is curtailed by tissue toxicities termed immune-related adverse events (irAEs), which occur most quickly and most often in the skin. We review the rationale for immune checkpoint blockade use, current agents, use in skin cancers, autoimmune manifestations in the skin, and considerations for predictive biomarkers and treatment options on the basis of skin pathogenesis. We also highlight major gaps in the field and the lack of preclinical modeling in the skin. A deeper understanding of irAE pathophysiology may help to uncouple toxicity and efficacy but mandates an interdisciplinary approach, including foundational skin immunology and autoimmune pathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available